Anemia
📧 Sign up to get email alerts when something new happens for Anemia.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2026-08-21EMA Suspended: Oxbryta (voxelotor) — Pfizer Europe MA EEIG
The EMA suspended Oxbryta (voxelotor) for treating sickle cell disease-related anemia.
-
CLINICAL_TRIALS withdrawal · 2025-05-02Clinical Trial Update: Donor Stem Cell Boost in Treating Patients With Low Blood Cells After Donor Stem Cell Transplant [NA]
This clinical trial update indicates that the study evaluating a donor stem cell boost for patients with low blood cell counts after a donor…
-
CLINICAL_TRIALS withdrawal · 2024-12-20Clinical Trial Update: HBOC-201 Expanded Access Protocol for Life-threatening Anemia for Whom Allogeneic Blood Transfusion is Not an Option
The HBOC-201 expanded access protocol for life-threatening anemia in patients without viable allogeneic transfusion options is no longer ava…
-
EMA withdrawal · 2024-10-08EMA Suspended: Oxbryta (voxelotor) — Pfizer Europe MA EEIG
The EMA has suspended the EU marketing authorization for Oxbryta (voxelotor) by Pfizer Europe MA EEIG, affecting its use for sickle cell dis…
-
EMA withdrawal · 2023-12-13EMA Application withdrawn: Jesduvroq (daprodustat) — GlaxoSmithKline Trading Services Limited
The EMA has withdrawn the marketing authorization application for Jesduvroq (daprodustat) by GlaxoSmithKline Trading Services Limited.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2023-09-29EMA Revoked: Adakveo (Crizanlizumab) — Novartis Europharm Limited
EMA has revoked Adakveo (crizanlizumab) marketed by Novartis Europharm Limited for sickle cell disease/anemia.
-
CLINICAL_TRIALS withdrawal · 2021-10-26Clinical Trial Update: Single Versus Multi-Dose Oral Tranexamic Acid in Patients at High Risk for Blood Transfusion After Total Joint Arthroplasty [Phase 4]
A Phase 4 clinical trial evaluating single versus multi-dose oral tranexamic acid in high-risk patients for blood transfusion after total jo…
-
EMA withdrawal · 2020-02-11EMA Application withdrawn: Xyndari — Emmaus Medical Europe Ltd
EMA withdrew the application for Xyndari by Emmaus Medical Europe Ltd in the orphan medicine program for anemia and sickle cell disease.
-
CLINICAL_TRIALS withdrawal · 2019-02-21Clinical Trial Update: Oxytocin Dosing at Planned Cesarean Section and Anemia [Phase 4]
A Phase 4 trial evaluating oxytocin dosing during planned cesarean section was withdrawn, with relevance to anemia from blood loss and uteri…
-
CLINICAL_TRIALS withdrawal · 2018-11-05Clinical Trial Update: Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) [Phase 3]
Phase 3 trial evaluating three-times-per-week oral dosing of vadadustat for anemia in dialysis-dependent CKD has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-07-26Clinical Trial Update: Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study [NA]
A pilot clinical trial on patient-driven transfusion thresholds in hematological disorders sponsored by Emory University has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-06-14Clinical Trial Update: Capsule Endoscopy Versus Conservative Therapy for Obscure Gastrointestinal Bleeding [NA]
A clinical trial comparing capsule endoscopy to conservative therapy for obscure gastrointestinal bleeding has been withdrawn, with no resul…
-
CLINICAL_TRIALS withdrawal · 2018-03-05Clinical Trial Update: Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia [Phase 2]
Phase 2 trial evaluating the combination of iron and Procrit (epoetin alfa) in patients with advanced lung cancer and chemotherapy-induced a…
-
CLINICAL_TRIALS withdrawal · 2017-12-22Clinical Trial Update: Intravenous Iron in Patients With Severe Chronic Heart Failure and Chronic Kidney Disease [Phase 3]
A Phase 3 trial evaluating intravenous iron in patients with severe chronic heart failure and chronic kidney disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-11-21Clinical Trial Update: CliniMACS® CD34+ Reagent System for Expanded Access Use
This clinical trial update states that expanded-access use of the CliniMACS CD34+ Reagent System is no longer available.
-
CLINICAL_TRIALS withdrawal · 2016-09-20Clinical Trial Update: A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery. [Phase 3]
A Phase 3 trial evaluating epoetin alfa to reduce perioperative blood transfusions in hip replacement surgery has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-09-20Clinical Trial Update: A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) [Phase 2]
A Phase 2 trial of epoetin alfa in anemic patients with low- or intermediate-1 risk myelodysplastic syndromes has been withdrawn from develo…
-
CLINICAL_TRIALS withdrawal · 2016-09-20Clinical Trial Update: Open-Label Extension Safety Study of PROCRIT in Patients With Anemia of Chronic Disease Due to Rheumatoid Arthritis [Phase 2]
Open-label extension safety study of PROCRIT (epoetin alfa) in anemia of chronic disease due to rheumatoid arthritis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-08-24Clinical Trial Update: A Study of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia. [Phase 3]
A Phase 3 trial evaluating Mircera in hemodialysis patients with chronic renal anemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-06-28Clinical Trial Update: Furosemide Treatment Before Blood Transfusion in Patients With Systolic Dysfunction [NA]
The clinical trial examining furosemide before blood transfusion in patients with left ventricular systolic dysfunction has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-06-17Clinical Trial Update: Study to Evaluate Darbepoetin Alfa in Pediatric Subjects With Anemia Due to Chronic Kidney Disease [Phase 1]
A Phase 1 trial of darbepoetin alfa in pediatric patients with anemia due to chronic kidney disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-05-05Clinical Trial Update: Red Blood Cell Precursor Formulation to Determine Increased Production [Phase 2, Phase 3]
Phase 2/Phase 3 trial evaluating a red blood cell precursor formulation for increased production in anemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-03-24Clinical Trial Update: Erythropoietin Alfa in Elderly Subjects With Unexplained Anemia [NA]
A clinical trial evaluating erythropoietin alfa in elderly subjects with unexplained anemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-11-13Clinical Trial Update: Prednisone Plus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly [Phase 3]
A Phase 3 clinical trial evaluating prednisone plus chloroquine for hyper-reactive malarial splenomegaly has been withdrawn.
-
EMA withdrawal · 2015-07-13EMA Withdrawn: Rienso (Ferumoxytol) — Takeda Pharma A/S
EMA has withdrawn Rienso (ferumoxytol) from the market in Europe.